Introduction
============

Insulin-like growth factor 2 (*IGF2*) is an important mediator of cell growth and apoptosis that is paternally expressed. *IGF2* loss of imprinting (LOI) is predominantly indicated by the activation of the usually silenced maternal allele, with subsequent expression of the two gene copies ([@b1-ol-08-06-2561]). This is associated with a number of hereditary overgrowth conditions, including Beckwith-Wiedemann syndrome ([@b2-ol-08-06-2561]) and cancer that exhibits cell overgrowth resulting from *IGF2* overexpression ([@b3-ol-08-06-2561]). LOI has been reported in a variety of cancer types, in particular colorectal carcinoma ([@b4-ol-08-06-2561]--[@b6-ol-08-06-2561]). However, to the best of our knowledge, only one study examining LOI in lung carcinoma ([@b7-ol-08-06-2561]) has been published; LOI was detected in 47% adenocarcinomas, although the prevalence of LOI in squamous cell carcinomas was not mentioned. However, other studies have found the prevalence of LOI in squamous cell carcinomas and urothelial carcinomas in other organs to be relatively low. For example, the prevalence was found to be 21% in esophageal cancer ([@b8-ol-08-06-2561]) and 22% in bladder cancer ([@b9-ol-08-06-2561]). By contrast, the prevalence of LOI was 44--54% ([@b4-ol-08-06-2561],[@b7-ol-08-06-2561]) and 49% ([@b10-ol-08-06-2561]) in colorectal adenocarcinoma and gastric carcinoma, respectively. However, considerable variation has been reported.

Personalized cancer therapy has been applied to lung adenocarcinoma patients through the development of molecular-targeted therapeutic drugs against driver oncogenes. For example, lung adenocarcinoma patients with an epidermal growth factor receptor (*EGFR*) mutation or with an *ELM4*-*ALK* fusion protein have been shown to respond well to the corresponding drugs ([@b11-ol-08-06-2561]). Similarly, molecular-targeted therapy for insulin growth factors (IGFs) has been developed for a variety of cancer types, including non-small cell lung cancer ([@b12-ol-08-06-2561],[@b13-ol-08-06-2561]). Therapeutic methods that target the IGF1 receptor (IGF1R) have achieved certain success, although a modified therapy that targets and insulin receptor (IR) has proved more effective ([@b13-ol-08-06-2561]). IGF1 and IR are receptors for IGF2 that induce signal transduction resulting in cell growth; however, the IGF2 receptor interrupts IGF2 signal induction ([@b13-ol-08-06-2561]). Silencing of the *IGF2* gene was recently reported to result in apoptosis only for *IGF2* LOI colorectal carcinomas ([@b14-ol-08-06-2561]). Thus, *IGF2* LOI lung carcinoma appears to be a good candidate for molecular-targeted therapy.

To examine *IGF2* LOI, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) has been previously employed, but precise analysis is hampered by a number of problems, including lymphocyte contamination and heteroduplex formation during PCR ([@b15-ol-08-06-2561]). In the present study, the precise incidence of *IGF2* LOI in lung carcinomas was examined using PCR-RFLP in combination with DNA sequencing of samples obtained by a laser capture microdissection (LCM) method, as reported previously ([@b16-ol-08-06-2561]).

Materials and methods
=====================

Materials
---------

Tissue samples were obtained from 32 patients with lung cancer (19 with adenocarcinoma, 12 with squamous cell carcinoma and one with large cell carcinoma). Sections of carcinoma tissues and non-tumor lung tissue were removed and frozen immediately following surgery at Kanazawa University Cancer Research Hospital (Kanazawa, Japan). The tissues were stored at −80°C until further analysis.

LCM
---

Frozen 10-μm tissue sections were fixed with 70% ethanol for 10 min and stained with Kernechtrot (Merck, Darmstadt, Germany). A total of \~1,000 carcinoma cells in the frozen sections were punched out using a LCM system (LM100; Olympus Corporation, Tokyo, Japan) and collected on a plastic cap (CapSureTM LCM Caps; Arcturus, Mountain View, CA, USA). All specimens were assessed histologically by a pathologist (Professor E. Kawahara).

PCR-RFLP and direct sequencing
------------------------------

Genomic DNA from the frozen sections of the normal tissues was extracted using a Wizard^®^ SV Genomic DNA Purification system (Promega Corporation, Fitchburg, WI, USA). To extract total RNA from the microdissected carcinoma cells, a PicoPure™ RNA isolation kit (Arcturus) was used. The extracted RNA was further purified using the acid guanidinium phenol chloroform method, and possible contaminating DNAs were digested with DNase I (Takara, Tokyo, Japan). Aliquots of 1 μl extracted total RNA in a volume of 20 μl were converted to cDNA using AMV reverse transcriptase (Promega Corporation). The reverse transcription reaction was performed for 30 min at 42°C and then the sample was heated for 5 min at 99°C to inactivate the enzyme. Genomic DNA from normal whole tissues was amplified by PCR using the following primer pair for exon 9 of human *IGF2*: Forward, 5′-CTTGGACTTGAGTCAAATTGG-3′ and reverse, 5′-GGTCGTGCCAATTACATTTCA-3′. The tumor cDNAs obtained from the microdissection samples were amplified by nested PCR using the same primer pair followed by the second primer pair: Forward, 5′-CTTGGACTTTGAGTCAAATTGG-3′ and reverse, 5′-GGTTTTCATGCTCTGTCCTC-3′. The amplified 292 and 257 base-pair fragments were digested by *Apa*I (Toyobo, Osaka, Japan), which recognizes the C/T single nucleotide polymorphism site in the amplified area. Successful digestion of contaminating DNA was confirmed by PCR designed to amplify the exon-intron spanning region of the integrin β5 gene. Analysis of the polymorphism in the *IGF2* gene was then performed. The digested and undigested DNAs were run on 2% agarose gels containing ethidium bromide. The gel revealed three bands for heterozygotes, in which the restriction enzyme recognition sequence was present in one allele and absent in the other. The PCR products were also sequenced using Dye Terminator 1.1 (Applied Biosystems, Carlsbad, CA, USA) and ABI PRISM^®^ 3130×l Genetic Analyzer (Applied Biosystems).

Determination of imprinting status
----------------------------------

Digital images of the bands scanned into a computer were analyzed using the Image J software (National Institutes of Health, Bethesda, MD, USA). The band densities were measured and the ratio of the two bands was calculated. Similarly, the ratio of the two C and T peaks was calculated. The imprinting status was determined according to the criterion described in our previous study ([@b10-ol-08-06-2561]). In the case that two clear bands were detected with PCR-RFLP (ratio = 10--90%) and the sequence pattern revealed two clear peaks (ratio = 20--80%), the status was considered to be LOI; otherwise, the status was considered as imprinted.

Statistical analysis
--------------------

Statistical analyses were performed using StatMate software version 4.0 (ATMS, Co., Ltd., Tokyo, Japan) to perform the χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

Ethics
------

The study was approved by the Instititional Review Board for Analytical Research for Human Genome and Gene at Kanazawa University. All patients provided informed consent prior to sample collection according to the institutional guidelines.

Results
=======

LOI and imprinting status of lung carcinoma samples
---------------------------------------------------

The genomic DNA of whole non-tumor mucosa was employed to screen for whether the samples were informative or not, using the PCR-based, *IGF2* gene *Apa*I polymorphism. Of the 32 lung cancer cases, 23 (72%) were informative. All informative cases were examined for imprinting status in the microdissected carcinoma cells. The PCR products from the cDNA of the carcinoma cells revealed either two bands or a single band following *Apa*I analysis, and either two C and T peaks or one peak with a possible background peak subsequent to sequence analysis ([Fig. 1](#f1-ol-08-06-2561){ref-type="fig"}). Prior to determining whether the status was imprinted or LOI, the density ratio between the top and bottom bands, determined using PCR-RFLP, and the height ratio of the C and T peaks, examined using sequence analysis, were measured and calculated ([Table I](#tI-ol-08-06-2561){ref-type="table"}). Each case was identified as either imprinted or LOI, according to the criteria described above ([Table I](#tI-ol-08-06-2561){ref-type="table"}). LOI was detected in the adenocarcinoma and large cell carcinoma specimens, but was not detected in the squamous cell carcinoma samples. The percentage of LOI was 39% in total lung carcinomas (9 out of 23 cases) and 62% (8 out of 13 cases) in adenocarcinomas.

Association between LOI and histological grade
----------------------------------------------

Since a previous study concerning *IGF2* LOI in lung adenocarcinoma refers to histological type ([@b7-ol-08-06-2561]), the association between the histological grade of the adenocarcinoma sample and LOI was also analyzed in the present study. Four cases of well-differentiated adenocarcinoma were found to be LOI and one case of poorly differentiated adenocarcinoma was imprinted ([Table I](#tI-ol-08-06-2561){ref-type="table"}). These results do not support the previous suggestion that *IGF2* LOI occurs more frequently in poorly differentiated adenocarcinomas ([@b7-ol-08-06-2561]). Statistical analysis revealed no significant association between the degree of differentiation and LOI.

Discussion
==========

In the present study, the status of genomic imprinting of IGF2 in lung cancer was evaluated. IGF2 LOI was found to increase IGF2 signaling by increasing the proliferation of expression-related genes ([@b17-ol-08-06-2561]). We hypothesize that IGF2 LOI leads to an increased the risk of malignant transformation.

In this study, *IGF2* LOI was detected in half the cases of adenocarcinoma, but not in any cases of lung squamous cell carcinoma, which suggests an association between *IGF2* LOI and the histological type of the tumor. A number of adenocarcinoma-specific gene alterations are known, including *EGFR*, *KRAS* and *BRAF*, and these affect the gene products of the MAP kinase and PI3/AKT signaling pathways ([@b18-ol-08-06-2561],[@b19-ol-08-06-2561]). IGF2 binds to IR or IGF1R, thereby activating the same pathways ([@b12-ol-08-06-2561]). In this context, the effect of *IGF2* overexpression appears comparable with the effect of other gene alterations specific to adenocarcinoma.

The incidence of *IGF2* LOI in adenocarcinoma (62%) appears high as compared with other adenocarcinoma-specific gene alterations. However, the incidence of gene alteration may reflect population differences. A previous study indicated that the most frequent gene alteration in lung adenocarcinomas in Japanese patients is the *EGFR* mutation, with an incidence of 38%, while the most frequent gene alteration in Caucasians is *KRAS* mutation, with an incidence of 30% ([@b19-ol-08-06-2561]). The high incidence of the *IGF2* mutation in the present study, as compared with the incidences of other genes detected in previous studies, suggests an important role for the *IGF2* mutation in lung carcinogenesis.

In the present study, *IGF2* LOI was detected in approximately half of adenocarcinomas but not in any of the squamous cell carcinomas examined; thus, *IGF2* LOI may be a marker of lung adenocarcinoma. Distinguishing squamous cell carcinoma from adenocarcinoma of the lung is important, since the therapeutic methods employed are different and molecular analysis is guided by the histology. Molecular-targeted therapeutic drugs for activated *EGFR* have resulted in improvements in response rates and progression-free survival times in lung adenocarcinoma ([@b20-ol-08-06-2561]).

In conclusion, in the present study, *IGF*2 LOI was observed to occur at a high frequency in lung adenocarcinoma, but was not observed in squamous cell carcinoma. This result suggests that distinct carcinogenic pathways may exist for lung adenocarcinoma and squamous cell carcinoma, depending on the *IGF2* genomic imprinting status. Therefore, *IGF2* may have potential value as a diagnostic marker and therapeutic target.
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###### 

IGF2 status of laser-capture-microdissected carcinoma cells, defined as imprinted or LOI in informative cases, evaluated by PCR-RFLP in combination with direct sequencing.

  Case number   PCR (%T)   Sequence (%T)   Status      Histology              Differentiation of adenocarcinoma
  ------------- ---------- --------------- ----------- ---------------------- -----------------------------------
  1             0          12              Imprinted   SCC                    
  2             72         44              LOI         Adenocarcinoma         Well
  8             54         25              LOI         Adenocarcinoma         Well
  10            77         33              LOI         Adenocarcinoma         Well
  11            0          17              Imprinted   SCC                    
  12            0          18              Imprinted   SCC                    
  13            62         69              LOI         Adenocarcinoma         Moderate
  14            73         41              LOI         Large cell carcinoma   
  15            58         46              LOI         Adenocarcinoma         Moderate
  16            0          16              Imprinted   Adenocarcinoma         Moderate
  17            0          16              Imprinted   SCC                    
  18            0          11              Imprinted   Adenocarcinoma         Moderate
  19            9          17              Imprinted   Adenocarcinoma         Well
  20            7          16              Imprinted   Adenocarcinoma         Moderate
  21            5          16              Imprinted   SCC                    
  24            0          13              Imprinted   SCC                    
  25            0          3               Imprinted   Adenocarcinoma         Poor
  26            83         62              LOI         Adenocarcinoma         Poor
  28            100        85              Imprinted   SCC                    
  29            60         35              LOI         Adenocarcinoma         Moderate
  30            0          22              Imprinted   Adenocarcinoma         Well
  31            100        86              Imprinted   SCC                    
  32            0          9               Imprinted   SCC                    

The density ratios of the top and bottom bands (bottom/top+bottom) in PCR-RFLP and the height ratios of T and C peaks (T/T+C) in sequencing are listed. When only one band was identified with PCR-RFLP (ratio=10--90%) or the sequence pattern revealed a single peak (ratio = 20--80%), the status was considered to be LOI; otherwise, the status was considered to be imprinted. IGF2, insulin-like growth factor 2; LOI, loss of imprinting; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; SCC, squamous cell carcinoma.
